Current role of tenofovir DF in clinical practice;Papel actual de tenofovir en la clínica

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 8, 2008, Pages 45-54

  Ribera Pascuet, Esteban ^a   Curran, Adria ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

HIV infection; Initiation of antiretroviral therapy; Rescue therapy; Simplification of antiretroviral therapy; Tenofovir

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; STAVUDINE; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMETABOLITE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE;

ADVERSE OUTCOME; ANEMIA; ANTIGEN DETECTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STABILITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; GOLD STANDARD; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LIPODYSTROPHY; LIVER TOXICITY; LYMPHOCYTOPENIA; MITOCHONDRIAL TOXICITY; MIXED INFECTION; NEPHROTOXICITY; NEUTROPENIA; PANCREATITIS; PRACTICE GUIDELINE; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG COMBINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; LIVER DISEASE; META ANALYSIS; MULTIDRUG RESISTANCE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; VIRUS HEPATITIS;

ADENINE; ANTI-HIV AGENTS; ANTIMETABOLITES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; GLUCOSE METABOLISM DISORDERS; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIVER DISEASES; META-ANALYSIS AS TOPIC; PHOSPHONIC ACIDS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; THYMIDINE; VIRAL LOAD;

EID: 65549150919     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76531-5     Document Type: Article

References (61)

1. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Actualización Enero 2008 [accedido, 12 Mar 2008]. Disponible en: http://www.gesida.seimc.org/index.asp
2. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe [accedido 10 Abr 2008]. Disponible en: http://www.eacs.eu/guide/index.htm
3. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 29, 2008;1-128 [accedido 12 Mar 2008]. Disponible en: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
4. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. British HIV Association. April 2008;1-46 [accedido 10 Abr 2008]. Disponible en: http://www.bhiva.org/cms1222194.asp
5. Bartlett J.A., Chen S.S., and Quinn J.B. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin Trials 8 (2007) 221-226
6. Gallant J.E., Staszewski S., Pozniak A.L., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naive patients: a 3- year randomized trial. JAMA 292 (2004) 191-201
7. Gallant J.E., DeJesús E., Arribas J.R., Pozniak A.L., Gazzard B., Campo R.E., et al. Tenofovir DF, emtricitabine and efavirenz vs. zidovudine, lamivudine and efavirenz for VIH. N Engl J Med 354 (2006) 251-260
8. Arribas J.R., Pozniak A.L., Gallant J.E., DeJesús E., Gazzard B., Campo R.E., et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 47 (2008) 74-78
9. Bernardino de la Serna J.I., Mora Rillo M., and Arriba López J.A. Datos clínicos I. Experienciea clínica de tenofovir en combinaciones con inhibidores no análogos de la transcriptasa inversa. Enf Infec Microbiol Clin (2008) 26 Extra 9
10. Valdez J.R., Cassetti I., Suleiman J.M., Etzel A., Zhong L., Holmes C.B., et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials 8 (2007) 381-390
11. Rey D., Schmitt M.P., Hoizey G., Meyer P., Chavanet P., Allavena C., et al. Early virologic non-response to once daily combination of lamivudine, tenofovir and nevirapine in ART-naïve HIV-infected patients: preliminary results of the DAUFIN study. 14th Conference on retroviruses and opportunistic infections. Los Angeles. February 25-28 (2007) Abstract P 503
12. Lapadula G., Torti., Quirós-Roldán E., Costarelli S., Tirelli V., and Carosi G. Risk of early virological failure to tenofovir/emtricitabine once daily plus nevirapine twice daily in HIV-infected patients naïve to antiretroviral therapy. 11th European AIDS Conference. Madrid. October 24-27 (2007) Abstract P 7.3/10
13. Tong L.P.T., Robinson K.L., Babusis D., et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 51 (2007) 3498-3504
14. Kiser J.J., Carten M.L., Aquilante C.L., Anderson P.L., Wolfe P., King T.M., et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 83 (2008) 265-272
15. Cihlar T., Ray A.S., Laflamme G., Vela J.E., Tong L., Fuller M.D., et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 12 (2007) 267-272
16. Pulido F., and Fiorante S. Experiencia clínica de TDF en combinaciones con inhibidores de proteasa. Enf Infecc Microbiol Clin 26 (2008) Extra 9
17. Johnson M.A., Podzamczer D., Molina J.M., et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 43 (2006) 153-160
18. Gathe J., Loulfty M., Podzamczer D., et al. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir (LPV/r) tablets once daily (QD) versus twice daily (BID), co-administratered with tenofovir dt (TDF) + emtricitabine (FTC) in antiretroviral-naive (ARN) HIV-1 infected subjects. 15th Conference on Retrovirus and Opportunistic Infection. Boston. February 3-6 (2008) Abstract 775
19. Walmsley S.R.K., Slim J., Ward D., Larson P., and Raffi F. Saquinavir/r BiD versus lopinavir/r BiD, plus emtricitabine/tenofovir QD as initial therapy in HIV-1 infected patients: the GEMINI study. 11th European AIDS Conference. Madrid (2007) Abstract PS1/4
20. DeJesús E., Weinberg W., Ortiz R., Khanlou H., Voronin E., Van Lunzen J., Andrade-Villanueva J., et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1 infected patients at week 48: ARTEMIS (TMC114-C 211). 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, Illinois. September 17-20 (2007) Abstract H-718b
21. Smith K., Weinberg W., DeJesús E., et al. Once-daily ritonavir (100 mg) boosting of fosamprenavir or atazanavir with tenofovir/ emtricitabine in antiretroviral-naive HIV-infected patients: 48-week safety/efficacy results from COL103952 (ALERT). 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia. July 22-25 (2007) Abstract WEPEB023
22. Molina J.M., Echevarrua J., Chetchotisakd P., et al. Efficacy and safety of boosted oncee-daily atazanavir and twice-daily lopinavir regimens in treatment-naïve HIV-1 infected subjects (CASTLE study): 48-week results. 15th Conference on Retrovirus and Opportunistic Infection. Boston. February 3-6 (2008) Abstract 10
23. Smith K.F.D., Patel P., Bellos N., et al. Efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with once daily lopinavir/ritonavir through 48 weeks in the HEAT study. 15th Conference on Retrovirus and Opportunistic Infection. Boston. February 3-6 (2008) Abstract 774
24. ACTG5202. NIAID modifies HIV antiretroviral treatment study combination therapy that includes ABC/3TC found less effective in subgroup of antiretroviral-naïve individuals. Disponible en: http://www.3.niaid.nih.gov/news/newsreleases/2008/actg5202bulletin.htm
25. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 356 (2008) 1723-1735
26. Ribera E., Aguirrebengoa K., Miralles C., Antela A., Rivero A., and Arribas J.R. Simplificación del tratamiento antirretroviral. Enferm Infecc Microbiol Clin 20 Supl 2 (2002) 48-57
27. Portilla J. Tenofovir como estrategia para evitar o detener efectos adversos. Enf Infecc Microbiol Clin 26 (2008) Extra 9
28. Moyle G.J., Sabin C.A., Cartledge J., Johnson M., Wilkins E., Churchill D., et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20 (2006) 2043-2050
29. Ribera E, Paradineiro J, Curran A, et al. Improvements in subcutaneous fat, lipid profile and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST Study). Antivir Ther (submitted).
30. Milinkovic A., Martinez E., López S., et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 12 (2007) 407-415
31. Llibre J.M., Domingo P., Palacios R., Santos J., Pérez-Elías M.J., Sánchez-de la Rosa R., et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 20 (2006) 1407-1414
32. DeJesús E., Ruane P., McDonald C., et al. Effects of switching from fixed dose zidovudine/lamivudine to fixed dose tenofovir DF/emtricitabine: maintenance of virologic suppression and other benefits. 15th Annual Canadian Conference on HIV/AIDS Research. Quebec, Canada. May 25-28 (2006) Abstract 214
33. Moyle G., Fisher M., Reilly C., and The SWEET study group. A randomized comparison of the safety of continued zidovudine plus lamivudine (Combivir, CBV) versus switching to tenofovir DF plus emtricitabine (Truvada, TVD) each plus efavirenz (EFV) in stable HIV-infected persons: results of a planned 24-week analysis. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney. July 22-25 (2007) Abstract WEPEB028
34. Martínez E., Arranz J.A., Podzamczer D., et al. Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada) vs. abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney. July 22-25 (2007) Abstract WESS102
35. Carr A., Workman C., Smith D.E., et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288 (2002) 207-215
36. Martin A., Smith D.E., Carr A., et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18 (2004) 1029-1036
37. McComsey G.A., Ward D.J., Hessenthaler S.M., et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human im- munodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 38 (2004) 263-270
38. García-Benayas T., Blanco F., De la Cruz J.J., Soriano V., and González-Lahoz J. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS 17 (2003) 921-924
39. López Bernaldo de Quirós J.C. Tenofovir DF en pautas de rescate. Enf Infecc Microbiol Clin (2008) 26 Extra9:
40. Ribera E. Factores a consideraren terapia de rescate. Manual de manejo de nucleósidos en terapias de rescate (2007), EDIMSA, Madrid p. 7-31
41. Tuma P., Vispo E., Barreiro P., and Soriano V. Papel de tenofovir en la coinfección por VIH y VHC. Enf Infec Microbiol Clin (2008) 26 Estra 9:
42. Pineda J.A., García-García J.A., Aguilar-Guisado M., et al. Clinical Progression of Hepatitis C Virus-related chronic liver disease in HIV-infected patients undergoing highly active antiretroviral therapy. Hepatology 46 (2007) 611-614
43. Bräu N., Salvatore M., Ríos-Bedoya C.F., Fernández-Carbia A., Paronetto F., Rodríguez-Orengo J.F., et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatology 44 (2006) 47-55
44. Bani-Sadr F., Denoeud L., Morand P., et al. Early virologic failure in HIVcoinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?. J Acquir Immune Defic Syndr 45 (2007) 123-125
45. Vispo ME, Barreiro P, Pineda JA, et al. Low response to pegylated plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. En prensa 2008.
46. Crespo M., Pou L., Esteban J.I., Falcó V., Ribera E., Lopez R., et al. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir Ther 12 (2007) 1217-1223
47. Moreno A., Quereda C., Muriel A., et al. Does the choice of NRTIs have a significant influence on the outcome of peg-IFN plus ribavirin among HIV/HCV-co-infected Patients?. 15th Conference on Retroviruses and Opportunistic Infections. Boston, Mass. February 3-6 (2008) Abstract 1075
48. Sánchez-Conde M., Gil P., Sánchez-Somolinos M., González-Lahoz J., and Soriano V. Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin. HIV Clin Trials 6 (2005) 278-280
49. Pineda J., Mira J.A., Del Gil I., Valera-Bestard B., Rivero A., Merino D., et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 60 (2007) 1347-1354
50. Iser D.M., and Sasadeusz J.J. Current treatment of HIV/hepatitis B virus coinfection. J Gastroenterol Hepatol 23 (2008) 699-706
51. Soriano V., Puoti M., Bonacini M., et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV internationa panel. AIDS 19 (2005) 221-240
52. Thio C.L., Sulkowski M.S., and Thomas D.L. Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis 41 (2005) 1035-1040
53. Dore G.J., Cooper D.A., Pozniak A.L., et al., 903 Study Team; 907 Study Team. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 189 (2004) 1185-1192
54. Bani-Sadr F., Palmer P., Scieux C., and Molina J.M. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 39 (2004) 1062-1064
55. Nüesch R., Ananworanich J., Srasuebkul P., Chetchotisakd P., Prasithsirikul W., Klinbuayam W., et al. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS 22 (2008) 152-154
56. Bessesen M., Ives D., Condreay L., Lawrence S., and Sherman K.E. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28 (1999) 1032-1035
57. Matthews G.V., Cooper D.A., and Dore G.J. Improvements in parameters of endstage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antivir Ther 12 (2007) 119-122
58. Mallet V.O., Dhalluin-Venier V., Verkarre V., et al. Reversibility of cirrhosis in HIV/HBV coinfection. Antivir Ther 12 (2007) 279-283
59. DeJesús E., Herrera G., Teofilo E., et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39 (2004) 1038-1046
60. Berenguer J., González J., Ribera E., et al. Didanosine, lamivudine and efavirenz vs. zidovudine, lamivudine and efavirenz, for initial treatment of HIV infection. Final 48-week analysis of a prospective randomized non-inferiority clinical trial, GESIDA 3903. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, USA. September 17-20 (2007) Abstract 2300
61. European AIDS Clinical Society (EACS). Guidelines on the prevention and management of metabolic diseases in HIV [accedido, 12 Abr 2008]. Disponible en: http://www.eacs.eu/guide/index.htm